6.95

0.29% -0.02

After Hours: 6.97 0.02 +0.29%

Accolade Inc (ACCD)

Overview News Price History Option Chain Financials Why ACCD Down? Discussions Forecast

Accolade Inc stock is traded at $6.95, with a volume of 994.96K. It is down -0.29% in the last 24 hours and up +0.14% over the past month. Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.

Previous Close:

$6.97

Open:

$6.95

24h Volume:

994.96K

Relative Volume:

0.49

Market Cap:

$568.08M

Revenue:

$414.29M

Net Income/Loss:

$-99.81M

P/E Ratio:

-5.2068

EPS:

-1.3348

Net Cash Flow:

$-28.65M

1W Performance:

+0.43%

1M Performance:

+0.14%

6M Performance:

+63.92%

1Y Performance:

-30.22%

1-Day Range:

$6.95

$6.97

1-Week Range:

$6.93

$6.973

52-Week Range:

$3.08

$10.68

Accolade Inc Stock (ACCD) Company Profile

Name

Accolade Inc

Sector

Healthcare (1189)

Industry

Health Information Services (55)

Phone

610-834-2989

Address

660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING

Employee

2,400

Twitter

Next Earnings Date

2025-01-13

Latest SEC Filings

ACCD's Discussions on Twitter

Compare ACCD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACCD Accolade Inc	6.95	568.08M	414.29M	-99.81M	-28.65M	-1.3348
VEEV Veeva Systems Inc	218.95	35.98B	2.66B	665.91M	1.08B	4.05
SOLV Solventum Corp	80.16	13.98B	8.26B	66.00M	1.17B	0.3682
DOCS Doximity Inc	68.45	12.92B	516.85M	174.11M	217.38M	0.87
TEM Tempus Ai Inc	50.93	9.36B	640.44M	-743.28M	-206.93M	-11.29
HQY Healthequity Inc	104.82	9.34B	1.15B	96.70M	-161.99M	1.09

Accolade Inc Stock (ACCD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Reiterated	Needham	Buy
Feb-26-24	Initiated	Leerink Partners	Outperform
Jan-17-24	Resumed	DA Davidson	Neutral
Jan-03-24	Initiated	Barclays	Equal Weight
May-24-23	Upgrade	BofA Securities	Neutral → Buy
Apr-12-23	Initiated	Stephens	Overweight
Mar-23-23	Upgrade	Guggenheim	Neutral → Buy
Feb-09-23	Downgrade	Jefferies	Buy → Hold
Feb-02-23	Initiated	Raymond James	Outperform
Sep-08-22	Resumed	Piper Sandler	Overweight
Sep-07-22	Initiated	Truist	Buy
Aug-12-22	Initiated	DA Davidson	Buy
May-02-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Apr-29-22	Downgrade	BTIG Research	Buy → Neutral
Apr-29-22	Downgrade	BofA Securities	Buy → Neutral
Apr-29-22	Downgrade	Credit Suisse	Outperform → Neutral
Apr-29-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-29-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-11-22	Initiated	Wells Fargo	Underweight
Apr-07-22	Initiated	Guggenheim	Neutral
Apr-01-22	Resumed	Credit Suisse	Outperform
Feb-11-22	Initiated	Goldman	Buy
Dec-02-21	Initiated	Jefferies	Buy
Sep-30-21	Initiated	Berenberg	Buy
Sep-17-21	Upgrade	Robert W. Baird	Neutral → Outperform
May-28-21	Initiated	Robert W. Baird	Neutral
May-06-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Apr-15-21	Initiated	Needham	Buy
Mar-11-21	Resumed	Goldman	Buy
Jan-15-21	Upgrade	Credit Suisse	Neutral → Outperform
Jan-07-21	Initiated	BTIG Research	Buy
Dec-08-20	Initiated	Canaccord Genuity	Buy
Sep-22-20	Initiated	DA Davidson	Buy
Jul-27-20	Initiated	BofA Securities	Buy
Jul-27-20	Initiated	Credit Suisse	Neutral
Jul-27-20	Initiated	Goldman	Buy
Jul-27-20	Initiated	Morgan Stanley	Overweight
Jul-27-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Initiated	Robert W. Baird	Outperform
Jul-27-20	Initiated	SVB Leerink	Outperform

View All

Accolade Inc Stock (ACCD) Latest News

Mar 02, 2025